<VariationArchive RecordType="classified" VariationID="11103" VariationName="NM_000116.5(TAFAZZIN):c.580dup (p.Trp194fs)" VariationType="Duplication" Accession="VCV000011103" Version="3" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2023-12-25" DateCreated="2018-07-16" MostRecentSubmission="2022-12-24">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="26142" VariationID="11103">
      <GeneList>
        <Gene Symbol="TAFAZZIN" FullName="tafazzin, phospholipid-lysophospholipid transacylase" GeneID="6901" HGNC_ID="HGNC:11577" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154411539" stop="154421726" display_start="154411539" display_stop="154421726" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153639876" stop="153650064" display_start="153639876" display_stop="153650064" Strand="+" />
          </Location>
          <OMIM>300394</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000116.5(TAFAZZIN):c.580dup (p.Trp194fs)</Name>
      <CanonicalSPDI>NC_000023.11:154419742:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154419742" stop="154419743" display_start="154419742" display_stop="154419743" variantLength="1" positionVCF="154419742" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153648081" stop="153648082" display_start="153648081" display_stop="153648082" variantLength="1" positionVCF="153648081" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
      </Location>
      <ProteinChange>W164fs</ProteinChange>
      <ProteinChange>W194fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_131" sequenceAccession="LRG_131">
            <Expression>LRG_131:g.13209dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_131t1" sequenceAccession="LRG_131t1">
            <Expression>LRG_131t1:c.580dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_131p1" sequenceAccession="LRG_131p1" change="p.Trp194fs">
            <Expression>LRG_131p1:p.Trp194fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009634.2" sequenceAccession="NG_009634" sequenceVersion="2" change="g.13209dup">
            <Expression>NG_009634.2:g.13209dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181311.4" sequenceAccession="NM_181311" sequenceVersion="4" change="c.490dup">
            <Expression>NM_181311.4:c.490dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_851828.1" sequenceAccession="NP_851828" sequenceVersion="1" change="p.Trp164fs">
            <Expression>NP_851828.1:p.Trp164fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_024048.3" sequenceAccession="NR_024048" sequenceVersion="3" change="n.901dup">
            <Expression>NR_024048.3:n.901dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001303465.2" sequenceAccession="NM_001303465" sequenceVersion="2" change="c.595+120dup">
            <Expression>NM_001303465.2:c.595+120dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181312.4" sequenceAccession="NM_181312" sequenceVersion="4" change="c.541+120dup">
            <Expression>NM_181312.4:c.541+120dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181313.4" sequenceAccession="NM_181313" sequenceVersion="4" change="c.451+120dup">
            <Expression>NM_181313.4:c.451+120dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.153648082dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.153648082dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.154419743dup" Assembly="GRCh38">
            <Expression>NC_000023.11:g.154419743dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000116.5" sequenceAccession="NM_000116" sequenceVersion="5" change="c.580dup" MANESelect="true">
            <Expression>NM_000116.5:c.580dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000107.1" sequenceAccession="NP_000107" sequenceVersion="1" change="p.Trp194fs">
            <Expression>NP_000107.1:p.Trp194fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="TAZ_000065" DB="LOVD 3" />
        <XRef Type="Allelic variant" ID="300394.0004" DB="OMIM" />
        <XRef Type="rs" ID="2148211636" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff provided an HGVS expression for allelic variant 300394.0004 from the trace in Figure 4 of the paper by  Ades et al., 1993 (PubMed 8434619).</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000116.5(TAFAZZIN):c.580dup (p.Trp194fs) AND 3-Methylglutaconic aciduria type 2" Accession="RCV000011852" Version="9">
        <ClassifiedConditionList TraitSetID="3071">
          <ClassifiedCondition DB="MedGen" ID="C0574083">3-Methylglutaconic aciduria type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-02-02" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-02-02" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2018-07-16" MostRecentSubmission="2022-12-24">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">8434619</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8630491</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3071" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="487" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">3-methylglutaconicaciduria type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MGA type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cardioskeletal myopathy with neutropenia and abnormal mitochondria</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">3-Methylglutaconic aciduria type 2</ElementValue>
                <XRef ID="Barth+Syndrome/744" DB="Genetic Alliance" />
                <XRef ID="297231002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Barth syndrome</ElementValue>
                <XRef ID="MONDO:0010543" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MGCA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">BTHS</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MGA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5890" />
                <XRef ID="5890" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Barth syndrome is characterized in affected males by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and distinctive facial gestalt (most evident in infancy); not all features may be present in a given affected male. Cardiomyopathy, which is almost always present before age five years, is typically dilated cardiomyopathy with or without endocardial fibroelastosis or left ventricular noncompaction; hypertrophic cardiomyopathy can also occur. Heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. Neutropenia is most often associated with mouth ulcers, pneumonia, and sepsis. The nonprogressive myopathy predominantly affects the proximal muscles, and results in early motor delays. Prepubertal growth delay is followed by a postpubertal growth spurt with remarkable "catch-up" growth. Heterozygous females who have a normal karyotype are asymptomatic and have normal biochemical studies.</Attribute>
                <XRef ID="NBK247162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301486</ID>
                <ID Source="BookShelf">NBK1309</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25299040</ID>
                <ID Source="BookShelf">NBK247162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C5-OH Acylcarnitine, Organic Acidemias, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Organic Acidemias: Elevated C5-OH, 2022</CitationText>
              </Citation>
              <XRef ID="111" DB="Orphanet" />
              <XRef ID="C0574083" DB="MedGen" />
              <XRef ID="MONDO:0010543" DB="MONDO" />
              <XRef Type="MIM" ID="302060" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="32085" SubmissionDate="2022-03-21" DateLastUpdated="2022-03-28" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300394.0004_BARTH SYNDROME" title="TAFAZZIN, 1-BP INS, NT868_BARTH SYNDROME" />
        <ClinVarAccession Accession="SCV000032085" DateUpdated="2022-03-28" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1996-04-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In patient OAT with Barth syndrome (BTHS; 302060), previously reported by Ades et al. (1993), Bione et al. (1996) identified a 1-bp insertion in exon 7, after cDNA nucleotide 868, introducing a frameshift and stop codon after 201 amino acids.</Attribute>
              <Citation>
                <ID Source="PubMed">8434619</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">8630491</ID>
              </Citation>
              <XRef DB="OMIM" ID="302060" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TAFAZZIN" />
          </GeneList>
          <Name>TAFAZZIN, 1-BP INS, NT868</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, NT868</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300394.0004" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BARTH SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5413365" SubmissionDate="2022-12-21" DateLastUpdated="2022-12-24" DateCreated="2022-12-24">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000116_3_TAZ_c_580dupT" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002769079" DateUpdated="2022-12-24" DateCreated="2022-12-24" Type="SCV" Version="1" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8630491</ID>
          </Citation>
          <Comment>Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Barth syndrome (MIM#302060). (I) 0109 - This gene is associated with X-linked recessive disease. Typically female carriers do not manifest disease due to skewed X-inactivation of the mutant allele. However, affected females have been reported either due to biallelic mutation or monoallelic with skewed X-inactivation of the wild type allele (GeneReviews). (I) 0115 - Variants in this gene are known to have variable expressivity with intrafamilial variability (OMIM). (I) 0202 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction), but is located in an exon that may undergo alternative splicing. (SP) 0219 - This variant is non-coding in alternative transcripts, but is coding in the ClinVar predominant transcript. (I) 0253 - This variant is hemizygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0701 - Other NMD predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (DECIPHER). (SP) 0807 - This variant has no previous evidence of pathogenicity. It has been previously reported in this same family by Bione, S. et al. (PMID:8630491). (I) 0903 - This variant has limited evidence for segregation with disease. This variant was found in this proband, his unaffected mother and two affected male cousins (PMID: 8630491). (SP) 1007 - No published functional evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">X-linked recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TAZ" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_12737</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000116.3:c.580dupT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="302060" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_38</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="32085" TraitType="Disease" MappingType="Name" MappingValue="BARTH SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0574083" Name="3-Methylglutaconic aciduria type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5413365" TraitType="Disease" MappingType="XRef" MappingValue="302060" MappingRef="OMIM">
        <MedGen CUI="C0574083" Name="3-Methylglutaconic aciduria type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>